Nahdi Medical
النهديTechnical Analysis & Signals
Al Nahdi stock is experiencing a notable decline amid a downtrend with negative signals in technical indicators.
Technical Analysis
Technical analysis indicates that Al Nahdi stock is in a downtrend, with the Relative Strength Index (RSI) at 38.3, indicating weak momentum. Additionally, the MACD crossover suggests a continuation of the bearish trend.
Support & Resistance Levels
The main support level for the stock is at 99.6 SAR, while resistance is at 102.7 SAR. The stock is expected to test the support level, which may lead to further declines.
Volume Analysis
Volume data has not been provided, but a decline in trading volume is expected amid the current downtrend. This may indicate a lack of interest from investors at this time.
Fundamental Factors
The stock's Price-to-Earnings (P/E) ratio is 15.6, indicating a reasonable valuation. Additionally, the dividend yield is 5.91%, which may attract some investors despite the bearish trend.
Risk Factors
Potential risks include the continuation of the downtrend, which could lead to further losses. Additionally, general economic factors in the Saudi market may impact the stock's performance.
Recommendation
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. It is advisable to monitor support and resistance levels and make informed decisions based on technical and fundamental analysis.
Automated analysis is based on historical data and technical indicators and may not reflect future market conditions.
Financial Fundamentals
Price Data
Price Chart - Nahdi Medical
4164Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Within BandTrend Strength (ADX)
Weak TrendFinancial Summary
Valuation
- Market Cap
- 12.97B
- P/E Ratio
- 15.60
- P/B Ratio
- 4.70
- EPS (Earnings/Share)
- 6.39
Profitability
- Revenue
- 10.21B
- Net Income
- 830.74M
- Return on Equity (ROE)
- +30.00%
- Shares Outstanding
- 130.00M
Balance Sheet
- Total Assets
- N/A
- Total Debt
- 1.78B
- Debt/Equity
- 0.65
- Free Float %
- +29.9%
Dividends & Margins
- Dividend Yield
- +5.91%
- Dividend/Share
- 6.00
- Book Value
- 21.23
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
5 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2025 | 10.21B +8.1% | 830.74M +1.2% | 6.69B +8.4% | 1.78B +16.6% | 6.39 +1.3% |
| 2024 | 9.45B +8.4% | 820.72M -8.1% | 6.17B +14.9% | 1.53B +30.2% | 6.31 -8.2% |
| 2023 | 8.71B +1.1% | 892.62M +0.5% | 5.37B +8.6% | 1.17B +0.6% | 6.87 +0.6% |
| 2022 | 8.62B | 887.81M | 4.94B | 1.17B | 6.83 |
| 2021 | — | — | — | — | — |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
Tadawul-listed firms likely to announce dividends in March
GAC fines 13 companies, including 3 listed firms, for price fixing
Nahdi shareholders OK SAR 369.2M transfer to retained earnings
ANB Capital reviews Q4 2025 financials of four healthcare firms
AlJazira Capital sets potential changes in MSCI February index review
Key events shaping Saudi retail sector in Q4 2025
Analyst insights on Nahdi Q3 2025 results; TPs
Saudi-listed companies with highest, lowest profit growth in 9M 2025
News source: Argaam (argaam.com)
Sector Comparison
| Symbol | Name | Price | Change% |
|---|---|---|---|
| 4164 | Nahdi Medical | 99.80 SAR | |
| 4161 | BinDawood | 5.03 SAR | |
| 4001 | Abdullah Al Othaim Markets | 5.98 SAR | |
| 4163 | Al Dawaa | 49.04 SAR | |
| 4162 | Al Munjim | 60.90 SAR | |
| 4165 | Al Majed Oud | 137.60 SAR | |
| 4006 | Farm Superstores | 13.10 SAR | |
| 4061 | Anaam Holding | 10.72 SAR |
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-05-11
Risk Assessment
Risk Factors
Average True Range 2.2% of stock price
Trading volume near or above average
P/E ratio 15.6
Debt-to-equity ratio 0.65
ADX indicator at 15 — no clear direction
High volatility and financial pressures requiring careful monitoring
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is Nahdi Medical stock price today?
Nahdi Medical (4164) stock price today is 99.80 SAR, declining by -2.73% compared to the previous session close. The 52-week price range is between 88.46 SAR and 125.65 SAR.
2 What is Nahdi Medical stock valuation?
The automated analysis signal for Nahdi Medical is "Sell" with 70% confidence. The P/E ratio is 15.6. The P/B ratio is 4.70.
3 Is Nahdi Medical Shariah-compliant?
Yes, Nahdi Medical (4164) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are Nahdi Medical dividend distributions?
Nahdi Medical has a dividend yield of 5.91%, with an estimated annual dividend of 6.00 SAR per share.
5 What is Nahdi Medical weekly performance?
Nahdi Medical performance over different time periods: weekly change -3.95%, monthly -4.68%, and year-to-date +6.44%. The stock is currently trading with a volume of 320,297 shares.
6 What is the target level for Nahdi Medical?
According to automated analysis for Nahdi Medical: Short-term target (1-2 weeks): 95.00 SAR. Support level: 99.60 SAR. Resistance level: 102.70 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.